心脏衰竭与保存的喷射分数:如何处理这个驼
Fabiana Lucà1, Fabrizio Oliva2, Maurizio Giuseppe Abrignani3
1Cardiology Department, Grande Ospedale Metropolitano, 89129 Reggio Calabria, Italy.
Journal of clinical medicine
|April 9, 2024
概括
保存喷射分数 (HFpEF) 的心力衰竭是复杂而异质的. 本文概述了一种务实的方法来诊断和治疗HFpEF,强调个性化护理和管理相关疾病,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭在表型和病理生理学上呈现出显著的异质性.
- 随着年龄的增长和诸如肥胖,高血压和心脏代谢疾病等并发症的增加,导致HFpEF发病率的上升.
- 尽管取得了进展,但HFpEF仍未得到充分的认可和治疗,这给诊断和治疗带来了挑战.
研究的目的:
- 提出一种务实的,以病因学为重点的方法来管理患有HFpEF的患者.
- 提高对HFpEF特征的理解,包括伴随性疾病对预后的影响.
- 为了指导临床医生在诊断和治疗HFpEF.
主要方法:
- 对HFpEF病因,诊断和治疗的当前文献的综述.
- 强调多学科的团队方法,以提供全面的患者护理.
- 专注于个性化治疗策略,根据个体患者的个人资料和并发症量身定制.
主要成果:
- 个性化和准确的治疗管理改善生活质量,减少住院治疗,提高HFpEF患者的生存率.
- 解决并发症对于管理HFpEF症状和预后至关重要.
- 一种结构化,务实的方法可以提高临床识别和治疗疗效.
结论:
- HFpEF需要对个体患者的特征和并发症进行仔细评估.
- 多学科合作对于最佳的HFpEF管理至关重要.
- 本文为改善HFpEF诊断和治疗的务实方法提供了框架,最终有利于患者的结果.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337